Ring Christine 4

What Happened

• Christine Ring, Chief Legal Officer of Nurix Therapeutics (NRIX), had 10,534 restricted stock units (RSUs convert to one share each) vest and convert to common stock on Jan 30, 2026. A portion of those shares were sold to satisfy tax withholding requirements: 4,333 shares sold at $16.58 (proceeds $71,852) and 88 shares sold at $17.37 (proceeds $1,529), for total proceeds of $73,381. The remaining vested shares were withheld/cancelled to satisfy taxes (reported as conversions/dispositions at $0).

Key Details

• Transaction date: January 30, 2026 (reported same day).
• Vested/converted shares: 10,534 (exercised/converted at $0.00 per share).
• Open-market sales: 4,333 shares @ $16.58 and 88 shares @ $17.37; total proceeds $73,381 (overall weighted avg ≈ $16.60). Reported sale prices ranged from $16.33 to $17.49.
• Shares withheld/cancelled for taxes: 6,113 shares (10,534 vested minus 4,421 sold).
• Footnotes: Sales were mandatory “sell-to-cover” to satisfy tax withholding (not discretionary trades). RSUs represent contingent rights to one share and vest per prior award schedules.
• Shares owned after transaction: not disclosed in this Form 4.
• Filing timeliness: Filed for the reporting period dated Jan 30, 2026; no late filing indicated.

Context

• These transactions reflect RSU vesting and company-mandated sell-to-cover tax withholding rather than an opportunistic open-market trade. In such cases, sales are routine and intended to satisfy withholding obligations rather than signal insider sentiment.